[1]Goldenberg DM, Sharkey RM. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. Expert Opin Biol Ther. 2020 Aug;20(8):871-885. doi: 10.1080/14712598.2020.1757067. Epub 2020 May 12. PMID: 32301634.

[2]Fuentes-Antrás J, Genta S, Vijenthira A, Siu LL. Antibody-drug conjugates: in search of partners of choice. Trends Cancer. 2023 Apr;9(4):339-354. doi: 10.1016/j.trecan.2023.01.003. Epub 2023 Feb 4. PMID: 36746689.

[3] Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173-185. doi: 10.1248/cpb.c18-00744. PMID: 30827997.

[4]有效载荷毒性的相关文献: （a）Hinrichs MJ, Dixit R. Antibody Drug Conjugates: Nonclinical Safety Considerations. AAPS J. 2015;17(5):1055-1064. doi:10.1208/s12248-015-9790-0; (b) Fisher JE Jr. Considerations for the Nonclinical Safety Evaluation of Antibody-Drug Conjugates. Antibodies (Basel). 2021 Apr 19;10(2):15. doi: 10.3390/antib10020015. PMID: 33921632; PMCID: PMC8167597; (c) Masters JC, Nickens DJ, Xuan D, et al. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs. 2018 Feb; 36(1):121-135. （d）Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. PMID: 35320644.

[5]（a）Cytotoxic payloads for Antibody – Drug Conjugates, Hardback ISBN: 978-1-78801-077-1PDF ISBN: 978-1-78801-289-8EPUB ISBN: 978-1-78801-845-6. Publication date: 11 Jul 2019. DOI: http://doi.org/10.1039/9781788012898. (b) Cheng-Sánchez I, Moya-Utrera F, Porras-Alcalá C, López-Romero JM, Sarabia F. Antibody-Drug Conjugates Containing Payloads from Marine Origin. Mar Drugs. 2022 Jul 30;20(8):494. doi: 10.3390/md20080494. PMID: 36005497; PMCID: PMC9410405. （c）胡馨月，李艳萍，李卓荣，抗体药物偶联物的弹头分子研究进展，中国医药生物技术，2017， 012(006): 549-555. （d）Conilh L, Sadilkova L, Viricel W, Dumontet C. 有效载荷 diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023 Jan 17;16(1):3. doi: 10.1186/s13045-022-01397-y. PMID: 36650546; PMCID: PMC9847035.

[6]Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals (Basel). 2020 Sep 14;13(9):245. doi: 10.3390/ph13090245. PMID: 32937862; PMCID: PMC7558467.

[7]Pahl A, Lutz C, Hechler T. Amanitins and their development as a payload for antibody-drug conjugates. Drug Discov Today Technol. 2018 Dec;30:85-89. doi: 10.1016/j.ddtec.2018.08.005. Epub 2018 Sep 24. PMID: 30553524.

[8]Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR. A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. Cancer Cell. 2016 Jan 11;29(1):117-29. doi: 10.1016/j.ccell.2015.12.008. Erratum in: Cancer Cell. 2019 Jun 10;35(6):948-949. PMID: 26766593.

[9]Su D, Zhang D. Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency. Front Pharmacol. 2021 Jun 23;12:687926. doi: 10.3389/fphar.2021.687926. PMID: 34248637; PMCID: PMC8262647.

[10]Zhang D, Yu SF, Khojasteh SC, Ma Y, Pillow TH, Sadowsky JD, Su D, Kozak KR, Xu K, Polson AG, Dragovich PS, Hop CECA. Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates. Mol Cancer Ther. 2018 Mar;17(3):677-685. doi: 10.1158/1535-7163.MCT-17-0697. Epub 2018 Jan 18. PMID: 29348271.

[11]（a）Nilchan N, Li X, Pedzisa L, Nanna AR, Roush WR, Rader C. Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation. Antib Ther. 2019 Oct;2(4):71-78. doi: 10.1093/abt/tbz009. Epub 2019 Oct 24. PMID: 31930187; PMCID: PMC6953743. （b）Dragovich PS. Antibody-Drug Conjugates for Immunology. J Med Chem. 2022 Mar 24;65(6):4496-4499. doi: 10.1021/acs.jmedchem.2c00339. Epub 2022 Mar 14. PMID: 35285623. （c）Pillow TH, Adhikari P, Blake RA, Chen J, Del Rosario G, Deshmukh G, Figueroa I, Gascoigne KE, Kamath AV, Kaufman S, Kleinheinz T, Kozak KR, Latifi B, Leipold DD, Sing Li C, Li R, Mulvihill MM, O'Donohue A, Rowntree RK, Sadowsky JD, Wai J, Wang X, Wu C, Xu Z, Yao H, Yu SF, Zhang D, Zang R, Zhang H, Zhou H, Zhu X, Dragovich PS. Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity. ChemMedChem. 2020 Jan 7;15(1):17-25. doi: 10.1002/cmdc.201900497. Epub 2019 Nov 14. PMID: 31674143.